# PACIFIC-2 (NCT03519971)

> Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: durvalumab
- Indication: unresectable stage III NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03519971
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AstraZeneca
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Durvalumab; Placebo; Cisplatin/ Etoposide; Carboplatin/ Paclitaxel; Pemetrexed/ Cisplatin; Pemetrexed/ Carboplatin; Radiation
- Enrollment: 328
- Primary outcome: Progression-Free Survival (PFS)

## Indexed commentary on PACIFIC-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 126
- Podcasts: 31
- YouTube: 21
- Bluesky threads: 6
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=pacific-2-nct03519971

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03519971", "email": "<work email>"}; the inbox owner confirms by the emailed link.